Analysis of the efficacy and possible side effects of avatrombopag/sucoxin

Avatrombopag is a new oral thrombopoietin receptor agonist (TPO-RA). It mainly activates the thrombopoietin receptor (TPO-R), thereby promoting the proliferation and maturation of megakaryocytes in the bone marrow, thereby increasing the production of platelets and achieving the effect of treating thrombocytopenia. The drug is currently mainly suitable for two types of patients: one is adult patients who require elective diagnosis or surgery but have chronic liver disease leading to thrombocytopenia; the other is adult patients who suffer from chronic immune thrombocytopenia (ITP) and have poor response to initial treatment (such as glucocorticoids or immune globulin).

The biggest advantage of avatrombopag is its oral dosage form, stable efficacy, rapid onset of action, and its ability to significantly reduce blood transfusion dependence in some patients. It is especially suitable for clinical situations where platelets are increased short-term before surgery. Data from multiple overseas Phase III clinical trials (such as ADAPT-1, ADAPT-2, etc.) confirm that in patients with chronic liver disease-related thrombocytopenia, avatrombopag significantly increases preoperative platelet levels and effectively reduces the proportion of preoperative blood transfusions. For patients with chronic ITP, maintenance treatment with avatrombopag also shows good safety and the ability to continuously increase platelets. Compared with other TPO receptor agonists (such as eltrombopag and romiplostim), it does not contain the hepatotoxic benzenesulfonic acid structure and has no risk of significantly affecting liver function, so it has advantages in people with abnormal liver function.

Despite its outstanding efficacy, avatrombopag may also be associated with certain side effects. The most common adverse reactions include headache, fatigue, nausea, abdominal pain and constipation, which are usually mild to moderate and reversible. In some patients, abnormal liver function indicators such as mild elevation of ALT or AST have also been reported, but there is no risk of clinical severe liver injury. In addition, a very small number of patients may experience excessive platelet elevation (>450 × 10⁹/L), which requires close monitoring because it may induce the risk of thrombosis, especially in patients with existing cardiovascular and cerebrovascular disease risks. In addition, for long-term medication in patients with immune thrombocytopenia, platelet count and liver and kidney function need to be monitored regularly to prevent drug accumulation or overdose.

Avatrombopag is currently on the market in China, the United States, Europe and other countries or regions, and has been included in the treatment guideline recommendations of corresponding countries. Especially in China, the drug is included in the national medical insurance catalog as a Class B drug under the name of "Su Kexin", which greatly reduces the financial burden of patients. It should be noted that medical insurance reimbursement has clear indication restrictions and is only applicable to patients with chronic liver disease who have thrombocytopenia before elective surgery and ITP patients who meet the criteria. The application must be made after the doctor evaluates and fills out the corresponding form.

Overall, avatrombopag is an effective and safe drugTPO receptor agonists provide reliable pharmaceutical support in the treatment of chronic liver disease-related thrombocytopenia and refractory ITP. Its unique pharmacokinetic properties, good oral compliance and low liver toxicity make it stand out among many platelet-raising drugs. However, it still needs to be used under the guidance of a professional doctor and in conjunction with regular blood index monitoring to ensure double guarantees of safety and efficacy.

Reference materials:https://go.drugbank.com/drugs/DB11995